Beautifully outlines the company, how their lead product's Chinese Approval was fast-tracked because of the management of SARS which is a coronavirus
Outlines that USCOM 1A is currently widely adopted for the management and monitoring of infectious diseases in ICU's in China & other parts of the world and had it's approval extended a further 5 years
In the 4C published 2 weeks ago, they are forecasting to be cash flow positive this quarter
They also say that in the week post approval (early Jan) they received $400k in orders for their device (note quarterly burn is only 1m / qtr) so thats highly material
I dare say we are going to get a fresh update on their quarterly numbers in the coming days after they have been able to put it all together & not be rushed (as in on the back of a speedo)
There are 7 products in their approval pipeline for Chinese & US FDA approvals which they believe all will be obtained in the year to October (last October they said all 7 were expected in the following 12 months)
This stock is every fund managers dream for the following reasons:
- Regulatory approved medical device
- Already past the start up phase & commercialised
- Current Qtr goes in to Cash Flow Positive Mode
- Large target market for the devices globally
- Coronavirus outbreak meaning their device will be in high demand for the foreseeable future as ICUs in China are overwhelmed with patient demand
- Tight share holding registry with 2 directors owning 40% of the company
Holding on to this baby tight!!
UCM Price at posting:
24.5¢ Sentiment: Buy Disclosure: Held
